Shionogi & Co., Ltd. (TYO:4507)
2,547.00
+1.00 (0.04%)
Aug 1, 2025, 3:30 PM JST
Shionogi & Revenue
Shionogi & had revenue of 99.78B JPY in the quarter ending June 30, 2025, with 2.25% growth. This brings the company's revenue in the last twelve months to 440.50B, up 4.05% year-over-year. In the fiscal year ending March 31, 2025, Shionogi & had annual revenue of 438.27B with 0.73% growth.
Revenue (ttm)
440.50B
Revenue Growth
+4.05%
P/S Ratio
4.92
Revenue / Employee
88.90M
Employees
4,955
Market Cap
2,166.95B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 438.27B | 3.19B | 0.73% |
Mar 31, 2024 | 435.08B | 8.40B | 1.97% |
Mar 31, 2023 | 426.68B | 91.55B | 27.32% |
Mar 31, 2022 | 335.14B | 37.96B | 12.77% |
Mar 31, 2021 | 297.18B | -36.19B | -10.86% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.22B |
Daiichi Sankyo Company | 1,886.26B |
HOYA Corporation | 866.03B |
Takeda Pharmaceutical Company | 4,480.25B |
Otsuka Holdings | 2,393.18B |
Terumo | 1,036.17B |
Astellas Pharma | 1,944.99B |
Olympus | 997.33B |
Shionogi & News
- 4 days ago - Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Shionogi & Co. GAAP EPS of ¥200.29, revenue of ¥438.27B - Seeking Alpha
- 3 months ago - Shionogi to buy Japan Tobacco’s Torii Pharma in a deal worth over $1B - Seeking Alpha
- 6 months ago - Shionogi and Jordan's Guardian Angels Announce First-Ever Human Drug Study for Jordan's Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder - Benzinga
- 6 months ago - Shionogi & Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 6 months ago - Shionogi targets JPY550B revenue through QOL focus and global expansion - Seeking Alpha
- 6 months ago - Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Shionogi & Co. reports 9M results - Seeking Alpha